Sandoz has started construction of a new $440-million biosimilars production center for sterile product manufacturing in Brnik, Slovenia. The project brings the company’s total planned and ongoing investment in Slovenia to more than $1.1 billion by 2029.  

The project is part of ongoing investments in in-house capabilities to establish a fully integrated European biosimilar hub. They are in line with the existing capital expenditure commitments related to Sandoz operations in Slovenia.

The new investment adds to the company’s ongoing investments in Slovenia, namely a new biosimilar drug-substance production center in Lendava and a biosimilar development center in Ljubljana. 

Source: Sandoz